以海洋鱼骨胶原肽(Marine fish ossein peptide,MFOP)和氯化钙为原料制备多肽钙螯合物,应用Plackett-Burman设计、最陡爬坡试验和中心组合试验设计对螯合工艺进行优化,并对骨胶原肽及其螯合产物进行分子量分布测定和红外光谱分析。结果...以海洋鱼骨胶原肽(Marine fish ossein peptide,MFOP)和氯化钙为原料制备多肽钙螯合物,应用Plackett-Burman设计、最陡爬坡试验和中心组合试验设计对螯合工艺进行优化,并对骨胶原肽及其螯合产物进行分子量分布测定和红外光谱分析。结果表明,pH值和肽盐质量比对螯合率有极显著影响(P<0.01);优化后的螯合工艺参数:pH=5.90,温度50℃,时间60min,肽盐质量比5.05∶1,多肽浓度45g/L。在此条件下,多肽-钙螯合率为52.47%。凝胶色谱法测定结果显示,螯合物中肽分子量集中在1 000Da以下,其中小肽所占比例相对较大。红外光谱扫描结果显示,螯合产物在1 418cm-1出现羧酸根的伸缩振动峰,而在3 305cm-1处出现Ca-NH2伸缩振动峰,说明生成一种新型的海洋鱼骨胶原肽钙螯合物,具有潜在的营养保健价值和功能应用前景。展开更多
Objective To explore Effects of marine collagen peptides （MCPs） on markers of metablic nuclear receptors, i.e peroxisome proliferator-activated receptor （PPARs）, liver X receptor （LXRs） and farnesoid X receptor ...Objective To explore Effects of marine collagen peptides （MCPs） on markers of metablic nuclear receptors, i.e peroxisome proliferator-activated receptor （PPARs）, liver X receptor （LXRs） and farnesoid X receptor （FXRs） in type 2 diabetic patients with/without hypertension. Method Study population consisted of 200 type 2 diabetic patients with/without hypertension and 50 healthy subjects, all of whom were randomly assigned to MCPs-treated diabetics （n=50）, placebo-treated diabetics （n=50）, MCPs-treated diabetics with hypertension （n=50）, placebo-treated diabetics with hypertension （n=50）, and healthy controls （n=50）. MCPs or placebo （water-soluble starch） were given daily before breakfast and bedtime over three months. Levels of free fatty acid, cytochrome P450, leptin, resistin, adiponectin, bradykinin, NO, and Prostacyclin were determined before intervention, and 1.5 months, and 3 months after intervention. Hypoglycemia and the endpoint events during the study were recorded and compared among the study groups. Result At the end of the study period, MCPs-treated patients showed marked improvement compared with patients receiving placebo. The protection exerted by MCPs seemed more profound in diabetics than in diabetics with hypertension. In particular, after MCPs intervention, levels of free fatty acid, hs-CRP, resistin, Prostacyclin decreased significantly in diabetics and tended to decrease in diabetic and hypertensive patients whereas levels of cytochrome P450, leptin, NO tended to decrease in diabetics with/without hypertension. Meanwhile, levels of adiponectin and bradykinin rose markedly in diabetics following MCPs administration. Conclusion MCPs could offer protection against diabetes and hypertension by affecting levels of molecules involved in diabetic and hypertensive pathogenesis. Regulation on metabolic nuclear receptors by MCPs may be the possible underlying mechanism for its observed effects in the study. Further study into its action may shed light on developm展开更多
基金grants from the National Key Technology R&D Program (No. 2006BAD27B01)Chinese Center for Disease Control and Prevention Dalone Foundation of Dietary Nutrition (No. DIC-200710)a grant from Shenzhen Bureau of Science Technology & Information (No. 200802002)
文摘Objective To explore Effects of marine collagen peptides （MCPs） on markers of metablic nuclear receptors, i.e peroxisome proliferator-activated receptor （PPARs）, liver X receptor （LXRs） and farnesoid X receptor （FXRs） in type 2 diabetic patients with/without hypertension. Method Study population consisted of 200 type 2 diabetic patients with/without hypertension and 50 healthy subjects, all of whom were randomly assigned to MCPs-treated diabetics （n=50）, placebo-treated diabetics （n=50）, MCPs-treated diabetics with hypertension （n=50）, placebo-treated diabetics with hypertension （n=50）, and healthy controls （n=50）. MCPs or placebo （water-soluble starch） were given daily before breakfast and bedtime over three months. Levels of free fatty acid, cytochrome P450, leptin, resistin, adiponectin, bradykinin, NO, and Prostacyclin were determined before intervention, and 1.5 months, and 3 months after intervention. Hypoglycemia and the endpoint events during the study were recorded and compared among the study groups. Result At the end of the study period, MCPs-treated patients showed marked improvement compared with patients receiving placebo. The protection exerted by MCPs seemed more profound in diabetics than in diabetics with hypertension. In particular, after MCPs intervention, levels of free fatty acid, hs-CRP, resistin, Prostacyclin decreased significantly in diabetics and tended to decrease in diabetic and hypertensive patients whereas levels of cytochrome P450, leptin, NO tended to decrease in diabetics with/without hypertension. Meanwhile, levels of adiponectin and bradykinin rose markedly in diabetics following MCPs administration. Conclusion MCPs could offer protection against diabetes and hypertension by affecting levels of molecules involved in diabetic and hypertensive pathogenesis. Regulation on metabolic nuclear receptors by MCPs may be the possible underlying mechanism for its observed effects in the study. Further study into its action may shed light on developm
